| Dr David A Goldscher, MD | |
|
3333 N Calvert St, Ste 500, Baltimore, MD 21218-6502 | |
| (410) 366-5600 | |
| (410) 889-4952 |
| Full Name | Dr David A Goldscher |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 3333 N Calvert St, Baltimore, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952304370 | NPI | - | NPPES |
| 118011800 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D0016770 (Maryland) | Primary |
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000347 |
News Archive
Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.
"In order to break the vicious cycle that leaves tropical diseases neglected, existing programs that diagnose and treat patients need to be expanded and medical research to develop simpler, more effective tools needs to be supported, according to a new report, Fighting Neglect, released Monday by Medecins Sans Frontieres/Doctors Without Borders (MSF)," the organization reports on its webpage.
"Long heralded as a model for the global response to HIV/AIDS, Brazil is intensifying its actions, at home and abroad, in the face of potential setbacks including an arising need for new treatment regimens, the resultant increase in drug prices and the debate over intellectual property rights," Inter Press Service reports.
In the first large, observational study with a control group in England and Wales, research funded by the NIHR Maudsley Biomedical Research Centre has found that Community Treatment Orders are associated with an increased risk of readmission as well as increased time spent in psychiatric hospitals, contrary to results from previous uncontrolled studies.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David A Goldscher, MD 1838 Greentree Rd, Ste 150, Baltimore, MD 21208 Ph: (410) 602-9262 | Dr David A Goldscher, MD 3333 N Calvert St, Ste 500, Baltimore, MD 21218-6502 Ph: (410) 366-5600 |
News Archive
Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.
"In order to break the vicious cycle that leaves tropical diseases neglected, existing programs that diagnose and treat patients need to be expanded and medical research to develop simpler, more effective tools needs to be supported, according to a new report, Fighting Neglect, released Monday by Medecins Sans Frontieres/Doctors Without Borders (MSF)," the organization reports on its webpage.
"Long heralded as a model for the global response to HIV/AIDS, Brazil is intensifying its actions, at home and abroad, in the face of potential setbacks including an arising need for new treatment regimens, the resultant increase in drug prices and the debate over intellectual property rights," Inter Press Service reports.
In the first large, observational study with a control group in England and Wales, research funded by the NIHR Maudsley Biomedical Research Centre has found that Community Treatment Orders are associated with an increased risk of readmission as well as increased time spent in psychiatric hospitals, contrary to results from previous uncontrolled studies.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 4 days ago
Dr. Leonard Anang Sowah, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |